PT - JOURNAL ARTICLE AU - Leidi, Antonio AU - Berner, Amandine AU - Dumont, Roxane AU - Dubos, Richard AU - Koegler, Flora AU - Piumatti, Giovanni AU - Vuilleumier, Nicolas AU - Kaiser, Laurent AU - Balavoine, Jean-François AU - Trono, Didier AU - Pittet, Didier AU - Chappuis, François AU - Kherad, Omar AU - Courvoisier, Delphine AU - Azman, Andrew S AU - Zaballa, María-Eugenia AU - Guessous, Idris AU - Stringhini, Silvia AU - , TI - Occupational risk of SARS-CoV-2 infection and reinfection during the second pandemic surge: a cohort study AID - 10.1101/2021.08.06.21261419 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.06.21261419 4099 - http://medrxiv.org/content/early/2021/08/08/2021.08.06.21261419.short 4100 - http://medrxiv.org/content/early/2021/08/08/2021.08.06.21261419.full AB - Objectives This cohort study including essential workers, assessed the□risk and incidence of SARS-CoV-2□infection during the second surge of COVID-19 according to baseline serostatus and occupational sector.Methods Essential workers were selected from a seroprevalence survey cohort in Geneva, Switzerland and were linked to a state centralized registry compiling SARS-CoV-2 infections. Primary outcome was the number of virologically-confirmed infections from serological assessment (between May and September 2020) to January 25, 2021, according to baseline antibody status and stratified by three pre-defined occupational groups (occupations requiring sustained physical proximity, involving brief regular contact or others). Secondary outcomes included the incidence of infection.Results 10457 essential workers were included (occupations requiring sustained physical proximity accounted for 3057 individuals, those involving regular brief contact, 3645, and 3755 workers were classified under “Other essential occupations”). After a follow-up period of over 27 weeks, 5 (0.6%) seropositive and 830 (8.5%) seronegative individuals had a positive SARS-CoV-2 test, with an incidence rate of 0.2 (95% CI 0.1 to 0.6) and 3.2 (95% CI 2.9 to 3.4) cases per person-week, respectively. Incidences were similar across occupational groups. Seropositive essential workers had a 93% reduction in the hazard (HR of 0.07, 95% CI 0.03 to 0.17) of having a positive test during follow-up with no significant between-occupational group difference.Conclusions A ten-fold reduction in the hazard of being virologically tested positive was observed among anti-SARS-CoV-2 seropositive essential workers regardless of their sector of occupation, confirming the seroprotective effect of a previous SARS-CoV2 exposure at least six months after infection.What is already known about this subject?Risk of SARS-CoV-2 reinfection is low in the general population and among healthcare workers.What are the new findings?A ten-fold reduction of risk of being virologically tested positive reinfection is observed among anti-SARS-CoV-2 seropositive essential workers of different activity sectors, regardless of their occupation-related risk of exposure.How might this impact on policy or clinical practice in the foreseeable future?Vaccination could be delayed in individuals with previous history of SARS-CoV-2 infection with serologic confirmation, regardless of their occupational exposure. These observations need to be confirmed for new SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Private Foundation of the Geneva University Hospitals, the Fondation des Grangettes and the Center for Emerging Viral Diseases (Geneva university Hospital and Geneva university)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The investigation conforms the principles of the Declaration of Helsinki and was approved as an amendment by the local Ethical Committee (Commission Cantonale d'Ethique de la Recherche, Geneva, Switzerland; CCER 2020-00881). All participants gave written informed consent at the time of recruitment.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available for consultation